argenx (ARGX) Q2 2026 earnings summary

Executive summary

• Achieved 18th consecutive quarter of growth, with Q2 2026 product net sales reaching $1.5 billion, up 60% year-over-year and 17% quarter-over-quarter, driven by VYVGART's expansion in MG, CIDP, and new seronegative MG indication.

• Operating profit for Q2 2026 was $494 million, up 146% year-over-year, with profit for the period at $472 million.

• Ended Q2 2026 with $5.2 billion in cash, cash equivalents, and current financial assets, up $744 million since the start of the year.

• Continued investment in pipeline and commercialization, with a focus on innovation, patient-centric execution, and expansion into new indications.

• Vision 2030 strategy targets 50,000 patients treated, 10 labeled indications, and five late-stage pipeline candidates by 2030.

Financial highlights

• Q2 2026 product net sales were $1.5 billion, up from $949 million in Q2 2025, with U.S. net sales at $1.3 billion, Japan $102 million (including a $25 million one-off benefit), rest of world $136 million, and $5 million from China supply.

• Operating profit was $494 million, and profit for the period was $472 million; basic EPS for Q2 2026 was $7.58.

• Cash, cash equivalents, and current financial assets totaled $5.2 billion at quarter end.

• Gross margin for Q2 2026 was $1.4 billion, with cost of sales at $145 million.

• R&D expenses for Q2 2026 were $486 million, and SG&A expenses were $417 million.

Outlook and guidance

• Expect continued growth for the remainder of 2026, with seronegative MG and potential ocular MG approval as growth drivers.

• Preparing for launches in autoimmune myositis and ocular MG, with organizational readiness and expanded field force.

• Registrational study readouts for autoimmune myositis (Q3 2026) and MMN (Q4 2026) expected.

• Pipeline advancement includes late-stage development for next-gen FcRn molecules and empasiprubart.

• VYVGART SC autoinjector launch planned for 2027 for all approved indications.